Dezecapavir vs Lenacapavir (Sunlenca)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV capsid · full HIV pipeline
Dezecapavir
Developed by ViiV Healthcare
NCT06039579 · Phase 2 · completed
This Phase 2 trial was randomized, double-blind (participant and investigator), and placebo-controlled, with 44 participants allocated across multiple dose groups of VH4004280 and VH4011499. The primary endpoint was the maximum change in plasma HIV-1 RNA during 10-day monotherapy; posted results for VH4011499 show mean declines of about -1.8 to -2.2 log10 in active arms versus -0.18 log10 in placebo, but no p-values or confidence intervals are reported. Because the groups are very small (6-7 active vs 3 placebo) and the statistical significance of the primary comparison is not documented, this constitutes real but limited evidence.
Next expected readout: February 2027 · NCT07934719 (registry estimate)
Reported efficacy
Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Part 1b: VH4011499 Dose Level 1 — Baseline (Day 1): 5.001 log10 c/mL (Standard Deviation 0.7304); Maximum change compared to Baseline (Day 1): -1.834 log10 c/mL (Standard Deviation 0.5141) | Part 1b: VH4011499 Dose Level 2 — Baseline (Day 1): 4.339 log10 c/mL (Standard Deviation 0.6185); Maximum change compared to Baseline (Day 1): -1.797 log10 c/mL (Standard Deviation 0.4544) | Part 2b: VH4011499 Pre-specified Dose — Baseline (Day 1): 4.96 log10 c/mL (Standard Deviation 0.7288); Maximum change compared to Baseline (Day 1): -2.165 log10 c/mL (Standard Deviation 0.431) vs Matching Placebo for VH4011499 — Baseline (Day 1): 4.714 log10 c/mL (Standard Deviation 0.7736); Maximum change compared to Baseline (Day 1): -0.176 log10 c/mL (Standard Deviation 0.1969) (unclear)
Result source: NCT06039579
Lenacapavir (Sunlenca)
Marketed by Gilead Sciences
NCT04143594 · Phase 2 · completed
The trial randomized 183 participants to lenacapavir-containing regimens or the active comparator B/F/TAF, but treatment was not blinded. The primary HIV-1 RNA suppression endpoint was a clinically relevant measure, yet all lenacapavir-versus-comparator comparisons were non-significant, so the results provide real but limited evidence for lenacapavir.
Next expected readout: March 2027 · NCT06749054 (registry estimate)
Reported efficacy
Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Cohort 1A: Lenacapavir 87.5 percentage of participants | Cohort 1B: Placebo to Lenacapavir 16.7 percentage of participants (met)
Result source: NCT04150068
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dezecapavir | Lenacapavir (Sunlenca) |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | 90.4% vs 92%vs B/F/TAFNCT0414359411 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Trial running · NCT06532656 |
| CD4 count, change (week 48) | —Not reported | 275 vs 248vs B/F/TAFNCT0414359411 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Dezecapavir
- —Not reported
- Lenacapavir (Sunlenca)
- 90.4% vs 92%vs B/F/TAFNCT04143594
11 other results
- 84.9% vs 92% NCT04143594
- 84.6% vs 92% NCT04143594
- 86.5% vs 92% NCT04143594
- 75.5% vs 92% NCT04143594
- 86.5% vs 92% NCT04143594
- 90.4% vs 96% NCT04143594
- 88.7% vs 96% NCT04143594
- 88.5% vs 96% NCT04143594
- 94.2% vs 100% NCT04143594
- 92.5% vs 100% NCT04143594
- 94.2% vs 100% NCT04143594
HIV-1 RNA 50 copies/mL or more (week 48)
- Dezecapavir
- —Not reported
- Lenacapavir (Sunlenca)
- —Trial running · NCT06532656
CD4 count, change (week 48)
- Dezecapavir
- —Not reported
- Lenacapavir (Sunlenca)
- 275 vs 248vs B/F/TAFNCT04143594
11 other results
- 262 vs 248 NCT04143594
- 245 vs 248 NCT04143594
- 204 vs 193 NCT04143594
- 213 vs 193 NCT04143594
- 220 vs 193 NCT04143594
- 195 vs 232 NCT04143594
- 220 vs 232 NCT04143594
- 211 vs 232 NCT04143594
- 172 vs 163 NCT04143594
- 158 vs 163 NCT04143594
- 206 vs 163 NCT04143594
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dezecapavir: 3 of 4 rows · Lenacapavir (Sunlenca): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dezecapavir | Lenacapavir (Sunlenca) |
|---|---|---|
| Dropout rate | 0%Dose Level 1a NCT06039579 · Phase 2 · combination · HIV · phase 2 show 17 more results—Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%1875 mg PiB NCT05393271 · Phase 1 · monotherapy 0%625 mg PiB NCT05393271 · Phase 1 · monotherapy 0%400 mg PiB NCT05393271 · Phase 1 · monotherapy 0%300 mg + Midazolam (MDZ) PiB NCT05393271 · Phase 1 · combination 0%200 mg PiB NCT05393271 · Phase 1 · monotherapy 0%200 mg PiB NCT05393271 · Phase 1 · monotherapy 0%200 mg Tablet NCT05393271 · Phase 1 · monotherapy 0%125 mg PiB NCT05393271 · Phase 1 · monotherapy 0%25 mg PiB NCT05393271 · Phase 1 · monotherapy | 21.2%Group 1: SC LEN+(F/TAF→ TAF)b NCT04143594 · Phase 2 · combination show 7 more results34%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · combination 30.8%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · combination 16.7%750 mg NCT03739866 · Phase 1 · registry result, not featured evidence 16.7%450 mg NCT03739866 · Phase 1 · registry result, not featured evidence 14.3%150 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%50 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%20 mg NCT03739866 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —Dose Level 1a NCT06039579 · Phase 2 · combination · HIV · phase 2 show 17 more results—Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —1875 mg PiB NCT05393271 · Phase 1 · monotherapy —625 mg PiB NCT05393271 · Phase 1 · monotherapy —400 mg PiB NCT05393271 · Phase 1 · monotherapy —300 mg + Midazolam (MDZ) PiB NCT05393271 · Phase 1 · combination —200 mg PiB NCT05393271 · Phase 1 · monotherapy —200 mg PiB NCT05393271 · Phase 1 · monotherapy —200 mg Tablet NCT05393271 · Phase 1 · monotherapy —125 mg PiB NCT05393271 · Phase 1 · monotherapy —25 mg PiB NCT05393271 · Phase 1 · monotherapy | 1.9%Group 1: SC LEN+(F/TAF→ TAF)b NCT04143594 · Phase 2 · combination show 7 more results0%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · combination 0%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · combination —750 mg NCT03739866 · Phase 1 · registry result, not featured evidence —450 mg NCT03739866 · Phase 1 · registry result, not featured evidence —150 mg NCT03739866 · Phase 1 · registry result, not featured evidence —50 mg NCT03739866 · Phase 1 · registry result, not featured evidence —20 mg NCT03739866 · Phase 1 · registry result, not featured evidence |
| Serious AEs | —Dose Level 1a NCT06039579 · Phase 2 · combination · HIV · phase 2 show 17 more results0%Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%1875 mg PiB NCT05393271 · Phase 1 · monotherapy 0%625 mg PiB NCT05393271 · Phase 1 · monotherapy 0%400 mg PiB NCT05393271 · Phase 1 · monotherapy 0%300 mg + Midazolam (MDZ) PiB NCT05393271 · Phase 1 · combination 0%200 mg PiB NCT05393271 · Phase 1 · monotherapy 0%200 mg PiB NCT05393271 · Phase 1 · monotherapy 0%200 mg Tablet NCT05393271 · Phase 1 · monotherapy 0%125 mg PiB NCT05393271 · Phase 1 · monotherapy 0%25 mg PiB NCT05393271 · Phase 1 · monotherapy | 7.7%Group 1: SC LEN+(F/TAF→ TAF)b NCT04143594 · Phase 2 · combination show 7 more results7.5%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · combination 13.5%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · combination 0%750 mg NCT03739866 · Phase 1 · registry result, not featured evidence 16.7%450 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%150 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%50 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%20 mg NCT03739866 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | Dose Level 1a influenza 14.3% (placebo 33.3%) proteinuria 14.3% (placebo 0%) rash 14.3% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 show 14 more resultsDose Level 1 headache 14.3% (placebo 0%) upper respiratory tract infection 14.3% (placebo 0%) alanine aminotransferase increased 0% (placebo 0%) NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 Dose Level 2 arthralgia 16.7% (placebo 0%) dermatophytosis 16.7% (placebo 0%) ear pain 16.7% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 Dose Level 2 asthenia 16.7% (placebo 0%) dermatitis acneiform 16.7% (placebo 0%) diarrhoea 16.7% (placebo 0%) NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 Pre-specified Dose nausea 28.6% (placebo 0%) alanine aminotransferase increased 14.3% (placebo 0%) aspartate aminotransferase increased 14.3% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 Pre-specified Dose vessel puncture site haematoma 28.6% (placebo 0%) headache 14.3% (placebo 0%) hypokalaemia 14.3% (placebo 0%) NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 1875 mg PiB total bile acids increased 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) activated partial thromboplastin time prolonged 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 625 mg PiB gastroenteritis 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) activated partial thromboplastin time prolonged 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 400 mg PiB dry skin 16.7% (placebo 0%) skin abrasion 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 300 mg + Midazolam (MDZ) PiB somnolence 25% (placebo 0%) dizziness 12.5% (placebo 0%) feeling abnormal 12.5% (placebo 0%) NCT05393271 · Phase 1 · combination 200 mg PiB activated partial thromboplastin time prolonged 33.3% (placebo 0%) blood triglycerides increased 16.7% (placebo 0%) lipase increased 16.7% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 200 mg PiB diarrhoea 33.3% (placebo 0%) headache 33.3% (placebo 0%) nausea 33.3% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 200 mg Tablet medical device site dermatitis 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) activated partial thromboplastin time prolonged 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 125 mg PiB medical device site dermatitis 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) activated partial thromboplastin time prolonged 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 25 mg PiB blood creatine phosphokinase increased 16.7% (placebo 20%) haematocrit decreased 16.7% (placebo 0%) haemoglobin decreased 16.7% (placebo 0%) NCT05393271 · Phase 1 · monotherapy | b injection site erythema 48.1% injection site swelling 32.7% injection site pain 28.8% NCT04143594 · Phase 2 · combination show 7 more resultsinjection site erythema 34% injection site swelling 34% injection site pain 26.4% NCT04143594 · Phase 2 · combination 750 mg injection site pain 80% (placebo 30%) injection site erythema 40% (placebo 10%) injection site nodule 40% (placebo 0%) NCT03739866 · Phase 1 · registry result, not featured evidence 450 mg injection site pain 66.7% (placebo 30%) upper respiratory tract infection 66.7% (placebo 0%) injection site erythema 33.3% (placebo 10%) NCT03739866 · Phase 1 · registry result, not featured evidence 150 mg injection site erythema 66.7% (placebo 10%) injection site pain 66.7% (placebo 30%) injection site induration 50% (placebo 10%) NCT03739866 · Phase 1 · registry result, not featured evidence 50 mg injection site pain 66.7% (placebo 30%) syphilis 33.3% (placebo 0%) acne 16.7% (placebo 0%) NCT03739866 · Phase 1 · registry result, not featured evidence 20 mg headache 33.3% (placebo 20%) anogenital dysplasia 16.7% (placebo 0%) conjunctivitis allergic 16.7% (placebo 0%) NCT03739866 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 9 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dezecapavir
show 2 more results
show 2 more results
Lenacapavir (Sunlenca)
show 16 more results
show 16 more results
show 11 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dezecapavir's landscape · Lenacapavir (Sunlenca)'s landscape